MFC Co

MFC Co Enterprise Value

The Enterprise Value (EV) of MFC Co (432980.KQ) as of Oct 25, 2026 is 22.46 B KRW. In the previous year, Enterprise Value (EV) was 32.66 B KRW — a change of -31.24% (lower).

Enterprise Value

22.46 BKRW

YoY

-31.24%

Last updated:

Enterprise Value (EV) of MFC Co is 2024 22.46 B KRW. Enterprise Value (EV) of MFC Co was 2023 32.66 B KRW. It decreases by -31.24% lower compared to the previous year.

The MFC Co Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2022
39.93 B KRW
Jan 1, 2023
32.66 B KRW
Jan 1, 2024
22.46 B KRW
The MFC Co Enterprise Value history
YEAREnterprise ValueYoY
22.46 BKRW-31.24%
32.66 BKRW-18.19%
39.93 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MFC Co Stock analysis

What does MFC Co do? MFC Co Ltd generates revenue primarily through the development and production of active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials for the pharmaceutical industry. The company focuses on creating basic pharmaceutical substances and raw material pharmaceuticals, serving clients in the pharmaceutical sector. Its products are sold to pharmaceutical manufacturers who require these materials for drug formulation. The company operates within the pharmaceutical research and development segment, targeting firms involved in drug production and formulation. MFC Co Ltd's business model centers on providing essential raw materials and intermediates to pharmaceutical companies. By specializing in API, KSM, and intermediate materials, the company supports the manufacturing processes of its clients. The firm's revenue streams are derived from the sale of these specialized pharmaceutical components to manufacturers who integrate them into their final drug products. The company's target market consists of pharmaceutical manufacturers requiring high-quality raw materials for their production lines. The company's core offerings include active pharmaceutical ingredients (API), key starting materials (KSM), and intermediate materials, which are critical for pharmaceutical manufacturing. These products are sold to pharmaceutical manufacturers as part of their supply chain. MFC Co Ltd's revenue is generated through the direct sale of these materials to clients in the pharmaceutical industry. The company's focus on R&D for pharmaceutical substances ensures a steady demand for its products from drug manufacturers seeking reliable suppliers. MFC Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MFC Co stock

Enterprise Value (EV) of MFC Co is 22.46 B KRW in 2024.

Enterprise Value (EV) of MFC Co changed from 32.66 B KRW to 22.46 B KRW, representing a -31.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) MFC Co since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s KRW, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' KRW varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s MFC Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — MFC Co

All Key Metrics — MFC Co